<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-159953" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Cefuroxime</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Omole</surname>
            <given-names>Adekunle E.</given-names>
          </name>
          <aff>Louisiana State University Health Sciences Center</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Awosika</surname>
            <given-names>Ayoola O.</given-names>
          </name>
          <aff>University of Illinois College of Medicine</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Patel</surname>
            <given-names>Preeti</given-names>
          </name>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Adekunle Omole declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Ayoola Awosika declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Preeti Patel declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>11</day>
          <month>1</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-159953.s1" sec-type="Indications">
        <title>Indications</title>
        <p content-type="pubmed-excerpt">Cefuroxime belongs to the second generation of cephalosporin antibiotics and is classified as a &#x003b2;-lactam agent.&#x000a0;Cefuroxime was approved by the U.S. Food and Drug Administration (FDA) in December 1987, and it exhibits broad-spectrum activity against both gram-positive and gram-negative organisms, making&#x000a0;the drug&#x000a0;effective for treating a wide range of bacterial infections.<xref ref-type="bibr" rid="article-159953.r1">[1]</xref><xref ref-type="bibr" rid="article-159953.r2">[2]</xref>&#x000a0;Cefuroxime&#x000a0;is frequently utilized for empirical therapy in community-acquired infections,&#x000a0;including&#x000a0;upper and lower respiratory tract infections, genitourinary tract infections, skin and soft tissue infections (SSTIs), and Lyme disease.</p>
        <p>
<bold>FDA-Approved Indications of Parenteral Cefuroxime</bold>
</p>
        <p><bold>Lower respiratory tract infections:</bold> Cefuroxime is recommended for treating lower respiratory tract infections caused by <italic toggle="yes">Streptococcus pneumonia</italic>, <italic toggle="yes">S pyogenes</italic>, <italic toggle="yes">Haemophilus influenzae</italic> (including ampicillin-resistant strains), <italic toggle="yes">Staphylococcus aureus</italic> (including&#x000a0;penicillinase- and non-penicillinase&#x02013;producing strains), and <italic toggle="yes">Klebsiella</italic> spp. The guidelines of the Infectious Diseases Society of America (IDSA) and the American Thoracic Society (ATS) endorse the use of cefuroxime for community-acquired pneumonia.<xref ref-type="bibr" rid="article-159953.r3">[3]</xref></p>
        <p><bold>Urinary tract infections:</bold> Cefuroxime is indicated for treating urinary tract infections (UTIs) caused by susceptible strains of&#x000a0;<italic toggle="yes">Klebsiella </italic>spp<italic toggle="yes">.</italic>&#x000a0;and&#x000a0;<italic toggle="yes">Escherichia coli</italic>.</p>
        <p><bold>Skin and skin structure infections:</bold> Cefuroxime is indicated for treating SSTIs caused by <italic toggle="yes">S&#x000a0;pyogenes</italic>,&#x000a0;<italic toggle="yes">S aureus</italic>&#x000a0;(including penicillinase- and non-penicillinase-producing strains),&#x000a0;<italic toggle="yes">E coli, Klebsiella</italic>&#x000a0;spp., and&#x000a0;<italic toggle="yes">Enterobacter</italic>&#x000a0;spp.</p>
        <p><bold>Septicemia:</bold> Cefuroxime is indicated for the treatment of septicemia caused by susceptible strains of&#x000a0;<italic toggle="yes">H influenzae</italic>&#x000a0;(including ampicillin-resistant strains),&#x000a0;<italic toggle="yes">S aureus</italic>&#x000a0;(including&#x000a0;penicillinase- and non-penicillinase&#x02013;producing strains),&#x000a0;<italic toggle="yes">E coli, S pneumoniae,&#x000a0;</italic>and&#x000a0;<italic toggle="yes">Klebsiella </italic>spp<italic toggle="yes">.</italic></p>
        <p><bold>Meningitis:</bold> Cefuroxime is effective for treating meningitis caused by&#x000a0;<italic toggle="yes">Neisseria meningitidis, S pneumoniae, H influenzae</italic>&#x000a0;(including ampicillin-resistant strains), and&#x000a0;<italic toggle="yes">S aureus</italic>&#x000a0;(including&#x000a0;penicillinase- and non-penicillinase&#x02013;producing strains).</p>
        <p><bold>Uncomplicated and disseminated gonococcal infections:</bold> Cefuroxime may be considered for treating susceptible strains of Neisseria gonorrhoeae (including&#x000a0;penicillinase- and non-penicillinase&#x02013;producing bacteria). Notably,&#x000a0;ceftriaxone is the preferred agent due to resistance.<xref ref-type="bibr" rid="article-159953.r4">[4]</xref></p>
        <p><bold>Bone and joint infections:</bold> Cefuroxime is effective against susceptible strains of&#x000a0;<italic toggle="yes">S aureus</italic>&#x000a0;(including&#x000a0;penicillinase- and non-penicillinase-producing strains).</p>
        <p>
<bold>FDA-Approved Indications of Oral Cefuroxime</bold>
</p>
        <p><bold>Pharyngitis or tonsillitis:</bold> Cefuroxime is indicated for the treatment of mild-to-moderate pharyngitis or tonsillitis in adult and pediatric patients aged 13 or older caused by susceptible strains of<italic toggle="yes">&#x000a0;S pyogenes.&#x000a0;</italic>Notably, the efficacy of cefuroxime in preventing rheumatic fever has not been established in clinical trials. In addition, the effectiveness of cefuroxime in treating penicillin-resistant <italic toggle="yes">S pyogenes</italic> has not been demonstrated.<xref ref-type="bibr" rid="article-159953.r5">[5]</xref></p>
        <p><bold>Acute bacterial otitis media:</bold> Cefuroxime is indicated for the treatment of acute bacterial otitis media due to susceptible strains of&#x000a0;<italic toggle="yes">H influenzae</italic>&#x000a0;(including &#x003b2;-lactamase&#x02013;producing strains),&#x000a0;<italic toggle="yes">S pneumoniae</italic>,<italic toggle="yes">&#x000a0;S pyogenes</italic>&#x000a0;or&#x000a0;<italic toggle="yes">Moraxella catarrhalis</italic>&#x000a0;(including &#x003b2;-lactamase&#x02013;producing strains).<xref ref-type="bibr" rid="article-159953.r6">[6]</xref></p>
        <p><bold>Acute bacterial maxillary sinusitis:</bold> Cefuroxime is effective for&#x000a0;treating&#x000a0;mild-to-moderate acute bacterial maxillary sinusitis in adult and pediatric patients aged 13 or older due to susceptible strains of&#x000a0;<italic toggle="yes">H influenzae</italic>&#x000a0;(non-&#x003b2;-lactamase-producing strains only) or&#x000a0;<italic toggle="yes">S pneumonia</italic>. The effectiveness of cefuroxime for sinusitis due to&#x000a0;<italic toggle="yes">H influenzae</italic>&#x000a0;(including &#x003b2;&#x02013;lactamase&#x02013;producing strains) or&#x000a0;<italic toggle="yes">M catarrhalis</italic>&#x000a0;in acute bacterial maxillary sinusitis has not been proven.</p>
        <p><bold>Acute bacterial exacerbations of chronic bronchitis:</bold> Cefuroxime is indicated for the treatment of mild-to-moderate acute exacerbations of chronic bronchitis in adult and pediatric patients aged 13 or older. This drug is effective against strains of <italic toggle="yes">H influenzae</italic> (&#x003b2;-lactamase&#x02013;negative strains), <italic toggle="yes">S pneumoniae</italic>, and <italic toggle="yes">H</italic>&#x000a0;<italic toggle="yes">parainfluenzae</italic> (&#x003b2;-lactamase&#x02013;negative strains).<xref ref-type="bibr" rid="article-159953.r7">[7]</xref></p>
        <p><bold>Uncomplicated UTIs:</bold> Cefuroxime is indicated for the treatment of uncomplicated UTIs in adult and pediatric patients aged 13 or older&#x000a0;caused by susceptible strains of <italic toggle="yes">E coli</italic>&#x000a0;or<italic toggle="yes">&#x000a0;Klebsiella pneumonia</italic>.<xref ref-type="bibr" rid="article-159953.r8">[8]</xref></p>
        <p><bold>Uncomplicated SSTIs:</bold> Cefuroxime is indicated for the treatment of uncomplicated SSTIs in adult and pediatric patients aged 13 or older, which is caused by susceptible strains of <italic toggle="yes">S&#x000a0;aureus</italic>&#x000a0;(including &#x003b2;-lactamase-producing strains) or&#x000a0;<italic toggle="yes">S pyogenes</italic>.</p>
        <p><bold>Early Lyme disease (erythema migrans):</bold> Cefuroxime is FDA-approved for the treatment of early Lyme disease in adults and pediatric patients aged 13 or older, which is caused by susceptible strains of Borrelia burgdorferi. The joint guidelines by the IDSA, American Academy of Neurology (AAN), and American College of Radiology (ACR) recommend cefuroxime for erythema migrans. Other preferred agents recommended in these guidelines include doxycycline or amoxicillin.<xref ref-type="bibr" rid="article-159953.r9">[9]</xref></p>
        <p>
<bold>Off-Label Uses</bold>
</p>
        <p>Cefuroxime is utilized off-label for intraabdominal infections,<xref ref-type="bibr" rid="article-159953.r10">[10]</xref>&#x000a0;antimicrobial prophylaxis in surgery,&#x000a0;<xref ref-type="bibr" rid="article-159953.r11">[11]</xref>&#x000a0;and odontogenic infections.<xref ref-type="bibr" rid="article-159953.r12">[12]</xref></p>
        <p>
<bold>Antimicrobial Stewardship</bold>
</p>
        <p>Although the list of bacterial susceptibility should guide the selection of appropriate antibiotics, it is crucial to incorporate clinical judgment and consider antimicrobial resistance. To prevent the development of drug-resistant bacteria and ensure the effectiveness of cefuroxime and other antibacterial drugs, one should only use them for treating or preventing infections caused by susceptible bacteria. Healthcare professionals should use available culture and susceptibility data to guide treatment selection. According to IDSA, facility-specific guidelines can standardize prescribing practices based on local epidemiology. In instances where such data are unavailable, susceptibility patterns may aid in selecting the appropriate therapy. Antimicrobial stewardship programs&#x000a0;promote the proper use of oral antibiotics and facilitate a timely transition from intravenous (IV) to oral antibiotics.<xref ref-type="bibr" rid="article-159953.r13">[13]</xref></p>
      </sec>
      <sec id="article-159953.s2" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Bacterial cell walls are strengthened by cross-linking peptidoglycan units through the action of penicillin-binding proteins (PBPs), specifically peptidoglycan transpeptidase.<xref ref-type="bibr" rid="article-159953.r14">[14]</xref> The peptidoglycan layer protects the cell wall from lysis. As a bactericidal agent, cefuroxime binds to PBPs via &#x003b2;-lactam rings. This binding inhibits the transpeptidation or cross-linking in the peptidoglycan cell wall synthesis of susceptible bacterial organisms.<xref ref-type="bibr" rid="article-159953.r2">[2]</xref><xref ref-type="bibr" rid="article-159953.r15">[15]</xref> Although PBP3 is the primary target of cefuroxime, it can also inhibit PBP 1a and PBP 1b.<xref ref-type="bibr" rid="article-159953.r16">[16]</xref><xref ref-type="bibr" rid="article-159953.r17">[17]</xref> This inhibition of the bacteria's ability to form a functional cell wall leads to death through osmotic lysis.<xref ref-type="bibr" rid="article-159953.r18">[18]</xref></p>
        <p>
<bold>Susceptible Organisms</bold>
</p>
        <p><bold>Gram-positive aerobic bacteria: </bold>These bacteria include&#x000a0;<italic toggle="yes">S aureus</italic>,&#x000a0;<italic toggle="yes">S epidermidis</italic>,&#x000a0;<italic toggle="yes">S pneumonia</italic>,<xref ref-type="bibr" rid="article-159953.r19">[19]</xref><italic toggle="yes">&#x000a0;</italic>and<italic toggle="yes"> S pyogenes.</italic></p>
        <p>Notably, cefuroxime is generally ineffective against most strains of enterococci (eg, <italic toggle="yes">Enterococcus faecalis</italic>). In addition, the medication does not effectively target methicillin-resistant <italic toggle="yes">Staphylococcus</italic>&#x000a0;<italic toggle="yes">aureus</italic>&#x000a0;(MRSA) and <italic toggle="yes">Listeria monocytogenes</italic>.</p>
        <p><bold>Gram-negative aerobic bacteria:</bold>&#x000a0;These bacteria include&#x000a0;<italic toggle="yes">Citrobacter </italic>spp<italic toggle="yes">.,&#x000a0;</italic><italic toggle="yes">Enterobacter </italic>spp<italic toggle="yes">.,&#x000a0;</italic><italic toggle="yes">E coli</italic>,<italic toggle="yes"> H influenzae</italic> (including methicillin-resistant strains),<xref ref-type="bibr" rid="article-159953.r20">[20]</xref><xref ref-type="bibr" rid="article-159953.r21">[21]</xref><italic toggle="yes">&#x000a0;H parainfluenza</italic>,&#x000a0;<italic toggle="yes">Klebsiella </italic>spp<italic toggle="yes">.</italic> (including <italic toggle="yes">K pneumonia</italic>),&#x000a0;<italic toggle="yes">M catarrhalis </italic>(including ampicillin- and cephalothin-resistant strains),&#x000a0;<italic toggle="yes">Morganella morganii</italic>,&#x000a0;<italic toggle="yes">N gonorrhoeae</italic> (including penicillinase- and non-penicillinase-producing strains),<xref ref-type="bibr" rid="article-159953.r22">[22]</xref><italic toggle="yes">&#x000a0;N meningitidis</italic>,<italic toggle="yes"> Proteus mirabilis</italic>,<italic toggle="yes"> Providencia rettgeri</italic>,<italic toggle="yes"> Salmonella </italic>spp<italic toggle="yes">.</italic>, and&#x000a0;<italic toggle="yes">Shigella </italic>spp<italic toggle="yes">.</italic></p>
        <p>Notably, in vitro tests have indicated resistance to cefuroxime in some strains of <italic toggle="yes">M morganii, Enterobacter cloacae, </italic>and<italic toggle="yes"> Citrobacter </italic>spp. Furthermore, cefuroxime is generally ineffective against&#x000a0;<italic toggle="yes">Pseudomonas</italic> and <italic toggle="yes">Campylobacter</italic> spp., <italic toggle="yes">Acinetobacter</italic>
<italic toggle="yes">calcoaceticus</italic>, and the majority of strains from&#x000a0;<italic toggle="yes">Serratia </italic>spp<italic toggle="yes">.</italic> and <italic toggle="yes">P</italic>&#x000a0;<italic toggle="yes">vulgaris</italic>.<xref ref-type="bibr" rid="article-159953.r23">[23]</xref><xref ref-type="bibr" rid="article-159953.r24">[24]</xref><xref ref-type="bibr" rid="article-159953.r25">[25]</xref></p>
        <p><bold>Anaerobic bacteria:</bold>&#x000a0;These bacteria include&#x000a0;<italic toggle="yes">Bacteroides</italic>,&#x000a0;<italic toggle="yes">Clostridium</italic>,&#x000a0;<italic toggle="yes">Fusobacterium</italic>,&#x000a0;<italic toggle="yes">Peptococcus</italic><italic toggle="yes">,</italic> and&#x000a0;<italic toggle="yes">Peptostreptococcus </italic>species<italic toggle="yes">.</italic></p>
        <p>Notably,&#x000a0;<italic toggle="yes">Clostridium difficile</italic> and most strains of<italic toggle="yes"> Bacteroides fragilis</italic> are resistant to cefuroxime.</p>
        <p>
<bold>Resistance</bold>
</p>
        <p>The global challenge of developing resistance to antibacterial agents is substantial. Bacteria primarily acquire resistance to cefuroxime through various mechanisms, as listed below.</p>
        <p><bold>Drug inactivation or modification:</bold>&#x000a0;Certain bacteria can produce &#x003b2;-lactamases, which can cause hydrolysis of the &#x003b2;-lactam ring of cefuroxime, thus hindering its bactericidal effects. Despite its susceptibility, cefuroxime exhibits high stability in the presence of most &#x003b2;-lactamase strains.<xref ref-type="bibr" rid="article-159953.r2">[2]</xref></p>
        <p><bold>Alteration of target or binding site:</bold>&#x000a0;Modifications occur in the binding site of cefuroxime's PBPs, rendering it ineffective against MRSA and penicillin-resistant strains of <italic toggle="yes">S pneumoniae</italic>.&#x000a0;MRSA possesses a resistant gene, <italic toggle="yes">mecA</italic>, encoding PBP 2a. PBP 2a differs from other PBPs, as its active site does not bind to methicillin or other &#x003b2;-lactam antibiotics. Consequently, acquiring <italic toggle="yes">mecA</italic> confers resistance to methicillin and &#x003b2;-lactam antibiotics, as their &#x003b2;-lactam ring cannot interact with PBP 2a.<xref ref-type="bibr" rid="article-159953.r26">[26]</xref></p>
        <p><bold>Alteration in cell membrane penetration:</bold>&#x000a0;This&#x000a0;phenomenon is predominantly observed in gram-negative bacteria due to the impermeable outer membrane of their cell wall. The diminished penetration of the antibiotic through the outer membrane of the bacteria prevents the drug from reaching the target PBPs. <italic toggle="yes">Pseudomonas aeruginosa</italic> provides an illustrative example of this mechanism.<xref ref-type="bibr" rid="article-159953.r27">[27]</xref><xref ref-type="bibr" rid="article-159953.r28">[28]</xref></p>
        <p>
<bold>Pharmacokinetics</bold>
</p>
        <p>Understanding the pharmacokinetic profile of cefuroxime is necessary for appropriate dosing, monitoring, and optimizing therapeutic outcomes. The fundamental aspects of cefuroxime's pharmacokinetics are mentioned below.<xref ref-type="bibr" rid="article-159953.r29">[29]</xref></p>
        <p><bold>Absorption:</bold>&#x000a0;Cefuroxime can be administered orally or parenterally. The parent molecule, cefuroxime, exhibits poor absorption after oral administration. Cefuroxime axetil, the ester prodrug form of cefuroxime, is effectively absorbed from the intestines and promptly converted to cefuroxime through hydrolysis by esterases in the mucosal cells of the gastrointestinal tract. Subsequently, it is released into the systemic circulation, significantly enhancing absorption in the presence of food.&#x000a0;</p>
        <p>The bioavailability of cefuroxime axetil tablets is about 37% on an empty stomach and increases to around 52% if taken after food. Following oral administration, adults typically reach peak serum concentration of cefuroxime in about 2 to 3 hours, while in children, it takes approximately 3 to 4 hours.<xref ref-type="bibr" rid="article-159953.r22">[22]</xref> Cefuroxime is rapidly absorbed into the bloodstream after intramuscular (IM) or IV injection, with the peak serum concentration achieved in about 2 to 3 minutes after IV administration.</p>
        <p><bold>Distribution:</bold> Cefuroxime exhibits a relatively small volume of distribution of 0.25 to 0.3 L/kg, with approximately 33% to 50% of the drug binding to plasma proteins. Cefuroxime&#x000a0;effectively penetrates various tissues, including tonsils, sinus tissues, lungs, bronchial mucosa, aqueous humor of the eye, and middle ear effusion. Notably, cefuroxime demonstrates good penetration into bone tissue&#x02014;a valuable attribute in treating odontogenic infections.<xref ref-type="bibr" rid="article-159953.r30">[30]</xref></p>
        <p><bold>Metabolism:</bold>&#x000a0;The active parent compound cefuroxime is produced from its ester prodrug.<xref ref-type="bibr" rid="article-159953.r31">[31]</xref></p>
        <p><bold>Elimination</bold>: Cefuroxime is excreted by the kidney as an unchanged drug, resulting in a high urinary concentration.<xref ref-type="bibr" rid="article-159953.r32">[32]</xref> Approximately 50% of the dose can be recovered in the urine within 12 hours. The elimination half-life of cefuroxime is about 1 to 2 hours in adults and 1.4 to 1.9 hours in children. The pharmacokinetics of cefuroxime is influenced by its renal excretion, with decreasing renal function increasing its half-life.<xref ref-type="bibr" rid="article-159953.r33">[33]</xref></p>
      </sec>
      <sec id="article-159953.s3" sec-type="Administration">
        <title>Administration</title>
        <p>
<bold>Available Dosage Forms and Strengths</bold>
</p>
        <p>Cefuroxime is available in various formulations, including oral tablets, oral suspension, and powder for injections. The oral tablet cefuroxime axetil is available in strengths of 250 mg and 500 mg. The oral suspensions are available in concentrations of 125 mg/5 mL and 250 mg/5 mL. The powder for injection form is supplied in vials containing 750 mg, 1.5 g, and 7.5 g of cefuroxime as cefuroxime sodium. Administration of the powder for injection can be done either via IM or IV route.</p>
        <p>
<bold>Adult Dosage</bold>
</p>
        <p>Cefuroxime is administered twice or&#x000a0;thrice daily, depending on the severity of the infection.<xref ref-type="bibr" rid="article-159953.r34">[34]</xref>&#x000a0;The tablets and oral suspension demonstrate non-bioequivalence, making them non-substitutable on a milligram-to-milligram basis.</p>
        <p><bold>Pharyngitis or tonsillitis:</bold> The&#x000a0;recommended dosage of cefuroxime is 250 mg PO every 12 hours for&#x000a0;10 days.</p>
        <p><bold>Acute bacterial maxillary sinusitis:</bold> The&#x000a0;recommended dosage of cefuroxime is 250 mg PO every 12 hours for 10 days.</p>
        <p><bold>Acute bacterial exacerbations of chronic bronchitis:</bold> The&#x000a0;recommended dosage of cefuroxime is 250 to 500 mg PO every 12 hours for 10 days. Alternatively, the suggested dosage for IV administration is 500 to 750 mg every 8 hours, with a switch to oral cefuroxime as soon as clinically possible.</p>
        <p><bold>Uncomplicated pneumonia:</bold>&#x000a0;The recommended dosage of cefuroxime is 750 mg administered IV or IM every 8 hours.</p>
        <p><bold>Uncomplicated skin and skin structure infections:</bold> The recommended dosage&#x000a0;of cefuroxime is 250 to 500 mg PO every 12 hours for 10 days. Alternatively, the suggested dosage for IV or IM administration is 750 mg every 8 hours, with a switch to oral&#x000a0;cefuroxime&#x000a0;as soon as clinically possible.</p>
        <p><bold>Uncomplicated UTIs:</bold> The recommended dosage&#x000a0;of cefuroxime is 125 to 250 mg PO every 12 hours for 7 to 10 days. Alternatively, the suggested dosage for IV or IM administration is 750 mg every 8 hours, with a switch to oral&#x000a0;cefuroxime&#x000a0;as soon as clinically possible.</p>
        <p><bold>Gonorrhea:</bold>&#x000a0;Cefuroxime is not the preferred choice due to bacterial resistance. The reference dosage per the product label for uncomplicated gonococcal infection is 1.5 g administered IM as a single dose at 2 anatomical sites and 1 g of oral probenecid.</p>
        <p><bold>Early Lyme disease:</bold>&#x000a0;The recommended dosage is 500 mg PO every 12 hours for 20 days&#x000a0;as per AAN/IDSA/ACR guidelines. Treatment for erythema migrans may be sufficient with a 14-day course, but carditis and arthritis may necessitate prolonged treatment.<xref ref-type="bibr" rid="article-159953.r9">[9]</xref></p>
        <p>
<bold>Pediatric Dosage&#x000a0;</bold>
</p>
        <p><bold>Pharyngitis or tonsillitis:</bold>&#x000a0;The recommended dosage for children aged 3 months to 12 years is 20 mg/kg/d PO every 12 hours for 10 days, with a maximum daily dosage of 500 mg/d.&#x000a0;Alternatively, for IV or IM administration, the dosage is&#x000a0;75 to 150 mg/kg/d every 8 hours for 10 days, with a maximum daily dosage of 6 g/d. The suggested dosage for individuals aged 12 and older is 250 mg PO every 12 hours for 10 days.</p>
        <p><bold>Acute bacterial maxillary sinusitis:</bold>&#x000a0;The recommended dosage for children aged 3 months to 12 years is 30 mg/kg/d of suspension PO every 12 hours for 10 days, with a maximum daily dosage of 1 g/d.&#x000a0;Alternatively, for IV or IM administration, the dosage is 75 to 150 mg/kg/d every 8 hours for 10 days, with a maximum daily dosage of 6 g/d. The suggested dosage for individuals&#x000a0;aged 12 or older is 250 mg PO every 12 hours for 10 days.</p>
        <p><bold>Acute otitis media:</bold>&#x000a0;The recommended dosage for children aged 3 months to 12 years is 30 mg/kg/d of suspension PO every 12 hours for 10 days, with a maximum daily dosage of 1 g/d.&#x000a0;Alternatively, for IV or IM administration, the dosage is&#x000a0;75 to 150 mg/kg/d every 8 hours for 10 days, with a maximum daily dosage of 6 g/d. The suggested dosage for individuals&#x000a0;aged&#x000a0;12&#x000a0;or older is 250 mg&#x000a0;PO&#x000a0;every 12 hours for 10 days.</p>
        <p><bold>Impetigo:</bold>&#x000a0;The recommended dosage for children aged 3 months to 12 years is 30 mg/kg/d of suspension PO every 12 hours for 10 days, with a maximum daily dosage of 1 g/d.&#x000a0;Alternatively, for IV or IM administration, the dosage is&#x000a0;75 to 150 mg/kg/d every 8 hours for 10 days, with a maximum daily dosage of 6 g/d. The suggested dosage for individuals&#x000a0;aged&#x000a0;12&#x000a0;or older is 250 mg&#x000a0;PO&#x000a0;every 12 hours for 10 days.</p>
        <p>
<bold>Specific Patient Populations</bold>
</p>
        <p><bold>Hepatic impairment:</bold> Cefuroxime has not been extensively studied in patients with hepatic impairment, and as a result, there are no specific recommendations regarding its use in this population. As the metabolism of cefuroxime is not dependent on hepatic function, dosage adjustment is not necessary in patients with hepatic impairment.<xref ref-type="bibr" rid="article-159953.r35">[35]</xref></p>
        <p><bold>Renal impairment:</bold>&#x000a0;The degree of the impairment determines the dosage adjustment of cefuroxime. In individuals with creatinine clearance (CrCl) levels ranging between 10 and 30 mL/min, the recommended frequency for standard individual dose administration is every 24 hours. In patients with&#x000a0;CrCl levels below 10 mL/min, the recommended frequency is every 48 hours. Those undergoing hemodialysis should receive an additional standard dose after each dialysis session. For IV or IM injection, the dosage should be reduced to 750 mg twice daily if CrCl is 10 to 20 mL/min and 750 mg once daily if CrCl is less than 10 mL/min. Cefuroxime is effectively removed by dialysis, and an additional dose should be given at the end of dialysis.<xref ref-type="bibr" rid="article-159953.r36">[36]</xref></p>
        <p><bold>Pregnancy considerations:</bold>&#x000a0;Cefuroxime is classified as an FDA pregnancy category B drug. The available data from published studies do not indicate any association between cefuroxime and major congenital disabilities, miscarriage, or adverse outcomes for the fetus or mother. Animal reproduction studies have revealed no evidence of fetal risk or impaired fertility. Although&#x000a0;considered safe in pregnancy, cefuroxime use should be limited to situations where it is deemed necessary.<xref ref-type="bibr" rid="article-159953.r37">[37]</xref>&#x000a0;The American College of Obstetricians and Gynecologists (ACOG) acknowledges cefuroxime as a viable off-label option for preventing infection during cesarean delivery.<xref ref-type="bibr" rid="article-159953.r38">[38]</xref></p>
        <p><bold>Breastfeeding considerations:</bold>&#x000a0;As cefuroxime is excreted in human milk, caution is required in lactating mothers. Potential adverse effects, such as diarrhea or thrush, may occur in breastfed infants. The concentration of cefuroxime in breast milk is typically low and depends on maternal dose, administration timing, and the presence of mastitis. Although adverse effects are not generally severe, careful monitoring is advised to ensure the well-being of breastfed infants.</p>
        <p><bold>Pediatric patients:</bold> The safety and efficacy of cefuroxime have not been established in pediatric patients younger&#x000a0;than 3&#x000a0;months. Currently, recommendations for treating infection with cefuroxime in this age group are absent.<xref ref-type="bibr" rid="article-159953.r2">[2]</xref>&#x000a0;The dosage of cefuroxime for pediatric patients is based on body weight.<xref ref-type="bibr" rid="article-159953.r39">[39]</xref></p>
        <p><bold>Older patients:</bold> Research indicates no significant disparities in safety and efficacy between older and younger patients. Given the substantial renal excretion of cefuroxime, caution is advised in dose selection for older patients due to their increased potential for decreased renal function.<xref ref-type="bibr" rid="article-159953.r2">[2]</xref><xref ref-type="bibr" rid="article-159953.r22">[22]</xref></p>
      </sec>
      <sec id="article-159953.s4" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>Similar to penicillins and most &#x003b2;-lactam antibiotics, cefuroxime is generally well-tolerated. However, cefuroxime may potentially lead to adverse drug reactions in some patients, as seen with other medications. The most commonly reported adverse drug reactions are gastrointestinal disturbances, including nausea, vomiting, and diarrhea.<xref ref-type="bibr" rid="article-159953.r22">[22]</xref>&#x000a0;Additional gastrointestinal adverse drug reactions include anorexia, abdominal pain, dizziness, and headache. In cases of parenteral&#x000a0;administration, local reactions at the injection site, including thrombophlebitis, can occur.</p>
        <p>Cefuroxime may elicit hypersensitivity reactions, including pruritis, urticaria, and skin rashes. In rare instances, severe reactions, such as anaphylaxis, drug fever, erythema multiforme, toxic epidermal necrolysis, and Stevens-Johnson syndrome, have been reported.<xref ref-type="bibr" rid="article-159953.r40">[40]</xref> Reports indicate decreased hemoglobin or hematocrit, eosinophilia, and prolonged prothrombin time associated with cefuroxime use.<xref ref-type="bibr" rid="article-159953.r41">[41]</xref><xref ref-type="bibr" rid="article-159953.r42">[42]</xref> Furthermore, elevations in bilirubin and liver enzymes,&#x000a0;including aspartate transaminase, alanine transaminase, and alkaline phosphatase, have been observed.</p>
        <p>Case reports have also documented instances of acute kidney injury attributed to cefuroxime.<xref ref-type="bibr" rid="article-159953.r43">[43]</xref> Furthermore, a post-marketing surveillance study identified a statistically significant elevated risk of delirium associated with several antibiotics, including cefuroxime.<xref ref-type="bibr" rid="article-159953.r44">[44]</xref>&#x000a0;Similar to all&#x000a0;broad-spectrum antibacterial agents, <italic toggle="yes">C difficile&#x02013;</italic>associated diarrhea and<italic toggle="yes">&#x000a0;</italic>pseudomembranous colitis have been noted during and after courses of cefuroxime.<xref ref-type="bibr" rid="article-159953.r2">[2]</xref></p>
        <p>
<bold>Drug-Drug Interactions</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Cefuroxime may interact with drugs that serve as substrates, inhibitors, or inducers of renal tubular secretion, including probenecid, furosemide, or penicillins. These interactions can influence the renal clearance and serum levels of cefuroxime by competing for or modifying the activity of organic anion transporters in the kidney. Notably, probenecid can increase the concentration of cefuroxime in the blood.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Drugs that decrease stomach acidity, such as proton pump inhibitors, H2-blockers, and antacids, may reduce the absorption of cefuroxime.<xref ref-type="bibr" rid="article-159953.r45">[45]</xref>&#x000a0;Therefore, it is recommended to administer cefuroxime axetil at least 1 hour before or after the intake of these drugs.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Cefuroxime may interact with highly protein-bound drugs, such as warfarin, phenytoin, or aspirin. These drugs can displace cefuroxime from its binding sites on plasma proteins, increasing its free fraction and potentially intensifying its antibacterial activity and adverse effects.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Clinicians should exercise caution when concurrently using cefuroxime with nephrotoxic drugs, such as aminoglycosides and potent diuretics.<xref ref-type="bibr" rid="article-159953.r46">[46]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-159953.s5" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>Cefuroxime is contraindicated in individuals with known or documented severe hypersensitivity or allergic/anaphylaxis reactions to penicillins, cephalosporins, or other drugs. Patients with a history of an anaphylactic response, Stevens-Johnson syndrome, or toxic epidermal necrolysis to penicillin should not receive cefuroxime or other cephalosporins.<xref ref-type="bibr" rid="article-159953.r47">[47]</xref> In patients with penicillin allergy, caution should be exercised when considering cefuroxime, and discontinuation of the medication is recommended if an allergic reaction occurs. Severe hypersensitivity reactions may require epinephrine and other emergency measures.<xref ref-type="bibr" rid="article-159953.r2">[2]</xref><xref ref-type="bibr" rid="article-159953.r22">[22]</xref></p>
        <p>
<bold>Warnings and Precautions</bold>
</p>
        <p>Caution should be exercised when administering cefuroxime to patients with prolonged prothrombin time or international normalized ratio, including those with poor nutritional status, renal disease, hepatic disease, prolonged antibiotic therapy, or those previously stabilized on anticoagulants. Administration of vitamin K may be necessary when warranted.</p>
        <p><bold>Laboratory interference:</bold> In patients taking cefuroxime, ferricyanide tests may lead to false-negative blood/plasma glucose results, while copper reduction tests may result in false-positive glucose readings in urine. It is recommended to use either the hexokinase or glucose oxidase method to determine plasma glucose levels in patients receiving cefuroxime.</p>
        <p><bold>Pseudomembranous colitis and<italic toggle="yes"> C difficile</italic>&#x000a0;infection:</bold> Broad-spectrum antibiotics, including cefuroxime, can disrupt the normal gastrointestinal flora, potentially leading to the development of pseudomembranous colitis. Healthcare practitioners are advised to use caution when prescribing cefuroxime, especially in patients with a history of pseudomembranous colitis or confirmed C<italic toggle="yes">&#x000a0;difficile</italic>-associated disease.<xref ref-type="bibr" rid="article-159953.r2">[2]</xref><xref ref-type="bibr" rid="article-159953.r48">[48]</xref> If the diagnosis is confirmed, discontinuation of cefuroxime is recommended, and further management with fluid and electrolytes, along with antibiotic agents effective against <italic toggle="yes">C difficile</italic> (oral vancomycin or fidaxomicin), may be necessary.<xref ref-type="bibr" rid="article-159953.r49">[49]</xref></p>
      </sec>
      <sec id="article-159953.s6" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Cefuroxime administration and dosing necessitate adjustment in the geriatric population and individuals with poor renal function. Monitoring renal function is crucial, particularly in critically ill patients receiving higher doses and older patients. Clinicians should also monitor prothrombin time in at-risk patients and liver enzymes in individuals with hepatic dysfunction.<xref ref-type="bibr" rid="article-159953.r2">[2]</xref><xref ref-type="bibr" rid="article-159953.r22">[22]</xref></p>
      </sec>
      <sec id="article-159953.s7" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>
<bold>Signs and Symptoms of Overdose</bold>
</p>
        <p>Cefuroxime toxicity may present with a range of clinical signs and symptoms. Overdose of cefuroxime can induce cerebral irritation, potentially resulting in seizures.<xref ref-type="bibr" rid="article-159953.r22">[22]</xref> The risk of toxicity is elevated in individuals with impaired renal function. Caution is advised when administering cefuroxime to patients with a history of seizures, particularly those with poor renal function.</p>
        <p>
<bold>Management of Overdose</bold>
</p>
        <p>Prompt recognition and management of cefuroxime toxicity are crucial for mitigating potential risks. Immediate discontinuation of the drug is imperative in cases of suspected overdose or adverse reactions. Supportive care, including fluid resuscitation and electrolyte repletion, may be necessary to address fluid and electrolyte imbalances. In severe cases, particularly those involving neurological manifestations or anaphylactic reactions, advanced life support measures, including airway management and the administration of epinephrine, may be warranted.<xref ref-type="bibr" rid="article-159953.r47">[47]</xref> In instances of hematologic toxicity, close monitoring of blood counts and, if necessary, hematopoietic growth factors or transfusion therapy may be indicated. Hemodialysis may be considered in cases of severe overdose or in patients with renal impairment to enhance drug clearance and alleviate potential toxicity.</p>
      </sec>
      <sec id="article-159953.s8" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Effective management of a patient's condition when administering cefuroxime involves collaboration among various disciplines. Patients with bacterial infections benefit from interprofessional teamwork, requiring coordination, communication, and collaboration among clinicians, nurses, pharmacists, and other healthcare professionals. The shared goal of management is to optimize patient outcomes while ensuring the safe use of cefuroxime. Healthcare professionals can provide comprehensive care, monitor for potential adverse drug effects, and adjust the treatment plan through effective teamwork to achieve the best possible outcome for their patients.</p>
        <p>Primary care clinicians, internists, and infectious disease (ID) specialists&#x000a0;are critical in accurately diagnosing a bacterial infection, ensuring the administration of cefuroxime, and determining the appropriate indication, dosage, and duration of therapy. They also monitor for potential adverse drug effects and evaluate the response to treatment. Nurse practitioners and physician assistants can closely monitor patients for possible adverse drug reactions. Clinical pharmacists contribute by educating patients on medication details, administration, possible side effects, and potential drug interactions. Patients actively participate in their management by regularly updating clinicians and nurses about their experiences and overall well-being during the course of treatment. This collaborative approach ensures comprehensive care and optimal outcomes.&#x000a0;</p>
        <p>A prospective 4-year study conducted from 2006 to 2009 evaluated 1444 adult ID specialists' consultations. The main specialties seeking consultations included cardiology, orthopedics, general medicine, hematology-oncology, gastroenterology, and pulmonary or critical care. The primary reason for seeking consultations was to select antibiotics, which accounted for 75% of cases. The study found that consultations with ID specialists significantly reduced inappropriate antimicrobial therapy and dual therapy use, emphasizing the crucial role of ID physicians in optimizing treatment plans.<xref ref-type="bibr" rid="article-159953.r50">[50]</xref> The implementation of antimicrobial stewardship programs is essential to reduce inappropriate antibiotic use, including cephalosporins such as cefuroxime.<xref ref-type="bibr" rid="article-159953.r13">[13]</xref>&#x000a0;However, emergency department care for severe bacterial infections should not be withheld. When a bacterial infection is suspected, it is advisable to begin treatment with broad-spectrum antibiotics. Subsequently, based on clinical improvement and microbiological results, antibiotic therapy can be refined to a more targeted or narrower spectrum.<xref ref-type="bibr" rid="article-159953.r51">[51]</xref></p>
        <p>Effective interprofessional teamwork among healthcare professionals is characterized by open communication and shared decision-making, which is crucial for enhancing patient outcomes associated with cefuroxime therapy. Optimal outcomes related to cefuroxime therapy necessitate open communication and an interprofessional team approach involving clinicians (MDs, DOs, NPs, and PAs), specialists, pharmacists, infection control, and clinical microbiologists.</p>
      </sec>
      <sec id="article-159953.s9">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=159953&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=159953">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/159953/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=159953">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-159953.s10">
        <title>References</title>
        <ref id="article-159953.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>O'Callaghan</surname>
                <given-names>CH</given-names>
              </name>
              <name>
                <surname>Sykes</surname>
                <given-names>RB</given-names>
              </name>
              <name>
                <surname>Griffiths</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Thornton</surname>
                <given-names>JE</given-names>
              </name>
            </person-group>
            <article-title>Cefuroxime, a new cephalosporin antibiotic: activity in vitro.</article-title>
            <source>Antimicrob Agents Chemother</source>
            <year>1976</year>
            <month>Mar</month>
            <volume>9</volume>
            <issue>3</issue>
            <fpage>511</fpage>
            <page-range>511-9</page-range>
            <pub-id pub-id-type="pmid">1259407</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159953.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Scott</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>Ormrod</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Goa</surname>
                <given-names>KL</given-names>
              </name>
            </person-group>
            <article-title>Cefuroxime axetil: an updated review of its use in the management of bacterial infections.</article-title>
            <source>Drugs</source>
            <year>2001</year>
            <volume>61</volume>
            <issue>10</issue>
            <fpage>1455</fpage>
            <page-range>1455-500</page-range>
            <pub-id pub-id-type="pmid">11558834</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159953.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Metlay</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Waterer</surname>
                <given-names>GW</given-names>
              </name>
              <name>
                <surname>Long</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Anzueto</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Brozek</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Crothers</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Cooley</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Dean</surname>
                <given-names>NC</given-names>
              </name>
              <name>
                <surname>Fine</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Flanders</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Griffin</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Metersky</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Musher</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Restrepo</surname>
                <given-names>MI</given-names>
              </name>
              <name>
                <surname>Whitney</surname>
                <given-names>CG</given-names>
              </name>
            </person-group>
            <article-title>Diagnosis and Treatment of Adults with Community-acquired Pneumonia. An Official Clinical Practice Guideline of the American Thoracic Society and Infectious Diseases Society of America.</article-title>
            <source>Am J Respir Crit Care Med</source>
            <year>2019</year>
            <month>Oct</month>
            <day>01</day>
            <volume>200</volume>
            <issue>7</issue>
            <fpage>e45</fpage>
            <page-range>e45-e67</page-range>
            <pub-id pub-id-type="pmid">31573350</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159953.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Barbee</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>St Cyr</surname>
                <given-names>SB</given-names>
              </name>
            </person-group>
            <article-title>Management of Neisseria gonorrhoeae in the United States: Summary of Evidence From the Development of the 2020 Gonorrhea Treatment Recommendations and the 2021 Centers for Disease Control and Prevention Sexually Transmitted Infection Treatment Guidelines.</article-title>
            <source>Clin Infect Dis</source>
            <year>2022</year>
            <month>Apr</month>
            <day>13</day>
            <volume>74</volume>
            <issue>Suppl_2</issue>
            <fpage>S95</fpage>
            <page-range>S95-S111</page-range>
            <pub-id pub-id-type="pmid">35416971</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159953.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>van Driel</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>De Sutter</surname>
                <given-names>AI</given-names>
              </name>
              <name>
                <surname>Thorning</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Christiaens</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Different antibiotic treatments for group A streptococcal pharyngitis.</article-title>
            <source>Cochrane Database Syst Rev</source>
            <year>2021</year>
            <month>Mar</month>
            <day>17</day>
            <volume>3</volume>
            <issue>3</issue>
            <fpage>CD004406</fpage>
            <pub-id pub-id-type="pmid">33728634</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159953.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dhuguru</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Zviagin</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Skouta</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>FDA-Approved Oximes and Their Significance in Medicinal Chemistry.</article-title>
            <source>Pharmaceuticals (Basel)</source>
            <year>2022</year>
            <month>Jan</month>
            <day>04</day>
            <volume>15</volume>
            <issue>1</issue>
            <pub-id pub-id-type="pmid">35056123</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159953.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yoon</surname>
                <given-names>HI</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>CH</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>DK</given-names>
              </name>
              <name>
                <surname>Park</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Yim</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>JY</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>CT</given-names>
              </name>
              <name>
                <surname>Chung</surname>
                <given-names>HS</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>YW</given-names>
              </name>
              <name>
                <surname>Han</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Yoo</surname>
                <given-names>CG</given-names>
              </name>
            </person-group>
            <article-title>Efficacy of levofloxacin versus cefuroxime in treating acute exacerbations of chronic obstructive pulmonary disease.</article-title>
            <source>Int J Chron Obstruct Pulmon Dis</source>
            <year>2013</year>
            <volume>8</volume>
            <fpage>329</fpage>
            <page-range>329-34</page-range>
            <pub-id pub-id-type="pmid">23874094</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159953.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Novelli</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Rosi</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Pharmacological properties of oral antibiotics for the treatment of uncomplicated urinary tract infections.</article-title>
            <source>J Chemother</source>
            <year>2017</year>
            <month>Dec</month>
            <volume>29</volume>
            <issue>sup1</issue>
            <fpage>10</fpage>
            <page-range>10-18</page-range>
            <pub-id pub-id-type="pmid">29271734</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159953.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lantos</surname>
                <given-names>PM</given-names>
              </name>
              <name>
                <surname>Rumbaugh</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Bockenstedt</surname>
                <given-names>LK</given-names>
              </name>
              <name>
                <surname>Falck-Ytter</surname>
                <given-names>YT</given-names>
              </name>
              <name>
                <surname>Aguero-Rosenfeld</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Auwaerter</surname>
                <given-names>PG</given-names>
              </name>
              <name>
                <surname>Baldwin</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Bannuru</surname>
                <given-names>RR</given-names>
              </name>
              <name>
                <surname>Belani</surname>
                <given-names>KK</given-names>
              </name>
              <name>
                <surname>Bowie</surname>
                <given-names>WR</given-names>
              </name>
              <name>
                <surname>Branda</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Clifford</surname>
                <given-names>DB</given-names>
              </name>
              <name>
                <surname>DiMario</surname>
                <given-names>FJ</given-names>
              </name>
              <name>
                <surname>Halperin</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Krause</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Lavergne</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Liang</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Meissner</surname>
                <given-names>HC</given-names>
              </name>
              <name>
                <surname>Nigrovic</surname>
                <given-names>LE</given-names>
              </name>
              <name>
                <surname>Nocton</surname>
                <given-names>JJJ</given-names>
              </name>
              <name>
                <surname>Osani</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Pruitt</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Rips</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Rosenfeld</surname>
                <given-names>LE</given-names>
              </name>
              <name>
                <surname>Savoy</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Sood</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Steere</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Strle</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Sundel</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Tsao</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Vaysbrot</surname>
                <given-names>EE</given-names>
              </name>
              <name>
                <surname>Wormser</surname>
                <given-names>GP</given-names>
              </name>
              <name>
                <surname>Zemel</surname>
                <given-names>LS</given-names>
              </name>
            </person-group>
            <article-title>Clinical Practice Guidelines by the Infectious Diseases Society of America (IDSA), American Academy of Neurology (AAN), and American College of Rheumatology (ACR): 2020 Guidelines for the Prevention, Diagnosis and Treatment of Lyme Disease.</article-title>
            <source>Clin Infect Dis</source>
            <year>2021</year>
            <month>Jan</month>
            <day>23</day>
            <volume>72</volume>
            <issue>1</issue>
            <fpage>e1</fpage>
            <page-range>e1-e48</page-range>
            <pub-id pub-id-type="pmid">33417672</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159953.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Solomkin</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Mazuski</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Bradley</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Rodvold</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Goldstein</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Baron</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>O'Neill</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Chow</surname>
                <given-names>AW</given-names>
              </name>
              <name>
                <surname>Dellinger</surname>
                <given-names>EP</given-names>
              </name>
              <name>
                <surname>Eachempati</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Gorbach</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hilfiker</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>May</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Nathens</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>Sawyer</surname>
                <given-names>RG</given-names>
              </name>
              <name>
                <surname>Bartlett</surname>
                <given-names>JG</given-names>
              </name>
            </person-group>
            <article-title>Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America.</article-title>
            <source>Clin Infect Dis</source>
            <year>2010</year>
            <month>Jan</month>
            <day>15</day>
            <volume>50</volume>
            <issue>2</issue>
            <fpage>133</fpage>
            <page-range>133-64</page-range>
            <pub-id pub-id-type="pmid">20034345</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159953.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bratzler</surname>
                <given-names>DW</given-names>
              </name>
              <name>
                <surname>Dellinger</surname>
                <given-names>EP</given-names>
              </name>
              <name>
                <surname>Olsen</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Perl</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Auwaerter</surname>
                <given-names>PG</given-names>
              </name>
              <name>
                <surname>Bolon</surname>
                <given-names>MK</given-names>
              </name>
              <name>
                <surname>Fish</surname>
                <given-names>DN</given-names>
              </name>
              <name>
                <surname>Napolitano</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Sawyer</surname>
                <given-names>RG</given-names>
              </name>
              <name>
                <surname>Slain</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Steinberg</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Weinstein</surname>
                <given-names>RA</given-names>
              </name>
              <collab>American Society of Health-System Pharmacists</collab>
              <collab>Infectious Disease Society of America</collab>
              <collab>Surgical Infection Society</collab>
              <collab>Society for Healthcare Epidemiology of America</collab>
            </person-group>
            <article-title>Clinical practice guidelines for antimicrobial prophylaxis in surgery.</article-title>
            <source>Am J Health Syst Pharm</source>
            <year>2013</year>
            <month>Feb</month>
            <day>01</day>
            <volume>70</volume>
            <issue>3</issue>
            <fpage>195</fpage>
            <page-range>195-283</page-range>
            <pub-id pub-id-type="pmid">23327981</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159953.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zawi&#x0015b;lak</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Nowak</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Odontogenic Head and Neck Region Infections Requiring Hospitalization: An 18-Month Retrospective Analysis.</article-title>
            <source>Biomed Res Int</source>
            <year>2021</year>
            <volume>2021</volume>
            <fpage>7086763</fpage>
            <pub-id pub-id-type="pmid">33532496</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159953.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Barlam</surname>
                <given-names>TF</given-names>
              </name>
              <name>
                <surname>Cosgrove</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Abbo</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>MacDougall</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Schuetz</surname>
                <given-names>AN</given-names>
              </name>
              <name>
                <surname>Septimus</surname>
                <given-names>EJ</given-names>
              </name>
              <name>
                <surname>Srinivasan</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Dellit</surname>
                <given-names>TH</given-names>
              </name>
              <name>
                <surname>Falck-Ytter</surname>
                <given-names>YT</given-names>
              </name>
              <name>
                <surname>Fishman</surname>
                <given-names>NO</given-names>
              </name>
              <name>
                <surname>Hamilton</surname>
                <given-names>CW</given-names>
              </name>
              <name>
                <surname>Jenkins</surname>
                <given-names>TC</given-names>
              </name>
              <name>
                <surname>Lipsett</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Malani</surname>
                <given-names>PN</given-names>
              </name>
              <name>
                <surname>May</surname>
                <given-names>LS</given-names>
              </name>
              <name>
                <surname>Moran</surname>
                <given-names>GJ</given-names>
              </name>
              <name>
                <surname>Neuhauser</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Newland</surname>
                <given-names>JG</given-names>
              </name>
              <name>
                <surname>Ohl</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Samore</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Seo</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Trivedi</surname>
                <given-names>KK</given-names>
              </name>
            </person-group>
            <article-title>Implementing an Antibiotic Stewardship Program: Guidelines by the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America.</article-title>
            <source>Clin Infect Dis</source>
            <year>2016</year>
            <month>May</month>
            <day>15</day>
            <volume>62</volume>
            <issue>10</issue>
            <fpage>e51</fpage>
            <page-range>e51-77</page-range>
            <pub-id pub-id-type="pmid">27080992</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159953.r14">
          <label>14</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Bui</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Preuss</surname>
                <given-names>CV</given-names>
              </name>
            </person-group>
            <chapter-title>Cephalosporins</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>3</month>
            <day>24</day>
            <pub-id pub-id-type="pmid">31855361</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159953.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Marx</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Fant</surname>
                <given-names>WK</given-names>
              </name>
            </person-group>
            <article-title>Cefuroxime axetil.</article-title>
            <source>Drug Intell Clin Pharm</source>
            <year>1988</year>
            <month>Sep</month>
            <volume>22</volume>
            <issue>9</issue>
            <fpage>651</fpage>
            <page-range>651-8</page-range>
            <pub-id pub-id-type="pmid">3063476</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159953.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Curtis</surname>
                <given-names>NA</given-names>
              </name>
              <name>
                <surname>Orr</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Ross</surname>
                <given-names>GW</given-names>
              </name>
              <name>
                <surname>Boulton</surname>
                <given-names>MG</given-names>
              </name>
            </person-group>
            <article-title>Competition of beta-lactam antibiotics for the penicillin-binding proteins of Pseudomonas aeruginosa, Enterobacter cloacae, Klebsiella aerogenes, Proteus rettgeri, and Escherichia coli: comparison with antibacterial activity and effects upon bacterial morphology.</article-title>
            <source>Antimicrob Agents Chemother</source>
            <year>1979</year>
            <month>Sep</month>
            <volume>16</volume>
            <issue>3</issue>
            <fpage>325</fpage>
            <page-range>325-8</page-range>
            <pub-id pub-id-type="pmid">116592</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159953.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dellamonica</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Cefuroxime axetil.</article-title>
            <source>Int J Antimicrob Agents</source>
            <year>1994</year>
            <month>Mar</month>
            <volume>4</volume>
            <issue>1</issue>
            <fpage>23</fpage>
            <page-range>23-36</page-range>
            <pub-id pub-id-type="pmid">18611587</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159953.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sarkar</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Yarlagadda</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Ghosh</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Haldar</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>A review on cell wall synthesis inhibitors with an emphasis on glycopeptide antibiotics.</article-title>
            <source>Medchemcomm</source>
            <year>2017</year>
            <month>Mar</month>
            <day>01</day>
            <volume>8</volume>
            <issue>3</issue>
            <fpage>516</fpage>
            <page-range>516-533</page-range>
            <pub-id pub-id-type="pmid">30108769</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159953.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jones</surname>
                <given-names>RN</given-names>
              </name>
            </person-group>
            <article-title>Can antimicrobial activity be sustained? An appraisal of orally administered drugs used for respiratory tract infections.</article-title>
            <source>Diagn Microbiol Infect Dis</source>
            <year>1997</year>
            <season>Jan-Feb</season>
            <volume>27</volume>
            <issue>1-2</issue>
            <fpage>21</fpage>
            <page-range>21-8</page-range>
            <pub-id pub-id-type="pmid">9127102</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159953.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zhanel</surname>
                <given-names>GG</given-names>
              </name>
              <name>
                <surname>Karlowsky</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Low</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Hoban</surname>
                <given-names>DJ</given-names>
              </name>
            </person-group>
            <article-title>Antibiotic resistance in respiratory tract isolates of Haemophilus influenzae and Moraxella catarrhalis collected from across Canada in 1997-1998.</article-title>
            <source>J Antimicrob Chemother</source>
            <year>2000</year>
            <month>May</month>
            <volume>45</volume>
            <issue>5</issue>
            <fpage>655</fpage>
            <page-range>655-62</page-range>
            <pub-id pub-id-type="pmid">10797089</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159953.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Richter</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Brueggemann</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>Huynh</surname>
                <given-names>HK</given-names>
              </name>
              <name>
                <surname>Rhomberg</surname>
                <given-names>PR</given-names>
              </name>
              <name>
                <surname>Wingert</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Flamm</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Doern</surname>
                <given-names>GV</given-names>
              </name>
            </person-group>
            <article-title>A 1997-1998 national surveillance study: Moraxella catarrhalis and Haemophilus influenzae antimicrobial resistance in 34 US institutions.</article-title>
            <source>Int J Antimicrob Agents</source>
            <year>1999</year>
            <month>Oct</month>
            <volume>13</volume>
            <issue>2</issue>
            <fpage>99</fpage>
            <page-range>99-107</page-range>
            <pub-id pub-id-type="pmid">10595568</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159953.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Perry</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Brogden</surname>
                <given-names>RN</given-names>
              </name>
            </person-group>
            <article-title>Cefuroxime axetil. A review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy.</article-title>
            <source>Drugs</source>
            <year>1996</year>
            <month>Jul</month>
            <volume>52</volume>
            <issue>1</issue>
            <fpage>125</fpage>
            <page-range>125-58</page-range>
            <pub-id pub-id-type="pmid">8799689</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159953.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jones</surname>
                <given-names>RN</given-names>
              </name>
              <name>
                <surname>Jenkins</surname>
                <given-names>SG</given-names>
              </name>
              <name>
                <surname>Hoban</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Pfaller</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Ramphal</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>In vitro efficacy of six cephalosporins tested against Enterobacteriaceae isolated at 38 North American medical centres participating in the SENTRY Antimicrobial Surveillance Program, 1997-1998.</article-title>
            <source>Int J Antimicrob Agents</source>
            <year>2000</year>
            <month>Jul</month>
            <volume>15</volume>
            <issue>2</issue>
            <fpage>111</fpage>
            <page-range>111-8</page-range>
            <pub-id pub-id-type="pmid">10854806</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159953.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fluit</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Jones</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Schmitz</surname>
                <given-names>FJ</given-names>
              </name>
              <name>
                <surname>Acar</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Gupta</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Verhoef</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Antimicrobial susceptibility and frequency of occurrence of clinical blood isolates in Europe from the SENTRY antimicrobial surveillance program, 1997 and 1998.</article-title>
            <source>Clin Infect Dis</source>
            <year>2000</year>
            <month>Mar</month>
            <volume>30</volume>
            <issue>3</issue>
            <fpage>454</fpage>
            <page-range>454-60</page-range>
            <pub-id pub-id-type="pmid">10722427</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159953.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jones</surname>
                <given-names>RN</given-names>
              </name>
              <name>
                <surname>Croco</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Kugler</surname>
                <given-names>KC</given-names>
              </name>
              <name>
                <surname>Pfaller</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Beach</surname>
                <given-names>ML</given-names>
              </name>
            </person-group>
            <article-title>Respiratory tract pathogens isolated from patients hospitalized with suspected pneumonia: frequency of occurrence and antimicrobial susceptibility patterns from the SENTRY Antimicrobial Surveillance Program (United States and Canada, 1997).</article-title>
            <source>Diagn Microbiol Infect Dis</source>
            <year>2000</year>
            <month>Jun</month>
            <volume>37</volume>
            <issue>2</issue>
            <fpage>115</fpage>
            <page-range>115-25</page-range>
            <pub-id pub-id-type="pmid">10863106</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159953.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lowy</surname>
                <given-names>FD</given-names>
              </name>
            </person-group>
            <article-title>Antimicrobial resistance: the example of Staphylococcus aureus.</article-title>
            <source>J Clin Invest</source>
            <year>2003</year>
            <month>May</month>
            <volume>111</volume>
            <issue>9</issue>
            <fpage>1265</fpage>
            <page-range>1265-73</page-range>
            <pub-id pub-id-type="pmid">12727914</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159953.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pang</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Raudonis</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Glick</surname>
                <given-names>BR</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Cheng</surname>
                <given-names>Z</given-names>
              </name>
            </person-group>
            <article-title>Antibiotic resistance in Pseudomonas aeruginosa: mechanisms and alternative therapeutic strategies.</article-title>
            <source>Biotechnol Adv</source>
            <year>2019</year>
            <season>Jan-Feb</season>
            <volume>37</volume>
            <issue>1</issue>
            <fpage>177</fpage>
            <page-range>177-192</page-range>
            <pub-id pub-id-type="pmid">30500353</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159953.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Laborda</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Hernando-Amado</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Mart&#x000ed;nez</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Sanz-Garc&#x000ed;a</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Antibiotic Resistance in Pseudomonas.</article-title>
            <source>Adv Exp Med Biol</source>
            <year>2022</year>
            <volume>1386</volume>
            <fpage>117</fpage>
            <page-range>117-143</page-range>
            <pub-id pub-id-type="pmid">36258071</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159953.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mendes</surname>
                <given-names>GD</given-names>
              </name>
              <name>
                <surname>Borges</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>de C&#x000e1;ssia Val</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Patni</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Reyar</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Monif</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Sereno</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Orellana</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>De Nucci</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Comparative bioavailability of cefuroxime axetil suspension formulations administered with food in healthy subjects.</article-title>
            <source>Arzneimittelforschung</source>
            <year>2010</year>
            <volume>60</volume>
            <issue>2</issue>
            <fpage>101</fpage>
            <page-range>101-5</page-range>
            <pub-id pub-id-type="pmid">20329659</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159953.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>DeAngelis</surname>
                <given-names>AF</given-names>
              </name>
              <name>
                <surname>Barrowman</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Harrod</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Nastri</surname>
                <given-names>AL</given-names>
              </name>
            </person-group>
            <article-title>Review article: Maxillofacial emergencies: oral pain and odontogenic infections.</article-title>
            <source>Emerg Med Australas</source>
            <year>2014</year>
            <month>Aug</month>
            <volume>26</volume>
            <issue>4</issue>
            <fpage>336</fpage>
            <page-range>336-42</page-range>
            <pub-id pub-id-type="pmid">25065769</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159953.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Khan</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Atiya</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Akhtar</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Yadav</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Qureshi</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Jaremko</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mahmood</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Optimization of a Cefuroxime Axetil-Loaded Liquid Self-Nanoemulsifying Drug Delivery System: Enhanced Solubility, Dissolution and Caco-2 Cell Uptake.</article-title>
            <source>Pharmaceutics</source>
            <year>2022</year>
            <month>Apr</month>
            <day>01</day>
            <volume>14</volume>
            <issue>4</issue>
            <pub-id pub-id-type="pmid">35456606</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159953.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shi</surname>
                <given-names>AX</given-names>
              </name>
              <name>
                <surname>Qu</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Zhuang</surname>
                <given-names>HH</given-names>
              </name>
              <name>
                <surname>Teng</surname>
                <given-names>XQ</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>WX</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>YP</given-names>
              </name>
              <name>
                <surname>Xiao</surname>
                <given-names>YW</given-names>
              </name>
              <name>
                <surname>Qu</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Individualized antibiotic dosage regimens for patients with augmented renal clearance.</article-title>
            <source>Front Pharmacol</source>
            <year>2023</year>
            <volume>14</volume>
            <fpage>1137975</fpage>
            <pub-id pub-id-type="pmid">37564179</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159953.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Viberg</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lannerg&#x000e5;rd</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Larsson</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Cars</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Karlsson</surname>
                <given-names>MO</given-names>
              </name>
              <name>
                <surname>Sandstr&#x000f6;m</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>A population pharmacokinetic model for cefuroxime using cystatin C as a marker of renal function.</article-title>
            <source>Br J Clin Pharmacol</source>
            <year>2006</year>
            <month>Sep</month>
            <volume>62</volume>
            <issue>3</issue>
            <fpage>297</fpage>
            <page-range>297-303</page-range>
            <pub-id pub-id-type="pmid">16934045</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159953.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Arulappen</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Danial</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Haron</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Hau</surname>
                <given-names>LC</given-names>
              </name>
              <name>
                <surname>Khan</surname>
                <given-names>AH</given-names>
              </name>
            </person-group>
            <article-title>The Impact of Antimicrobial Stewardship Program on Injudicious Use of Cefuroxime.</article-title>
            <source>Front Pharmacol</source>
            <year>2020</year>
            <volume>11</volume>
            <fpage>565818</fpage>
            <pub-id pub-id-type="pmid">33664664</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159953.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Okolicsanyi</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Venuti</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Orlando</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Xerri</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Pugina</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Pharmacokinetic studies of cefuroxime in patients with liver cirrhosis.</article-title>
            <source>Arzneimittelforschung</source>
            <year>1982</year>
            <volume>32</volume>
            <issue>7</issue>
            <fpage>777</fpage>
            <page-range>777-82</page-range>
            <pub-id pub-id-type="pmid">6889880</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159953.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bathini</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Jandoc</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Kuwornu</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>McArthur</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Weir</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Sood</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Battistella</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Muanda</surname>
                <given-names>FT</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Jain</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Garg</surname>
                <given-names>AX</given-names>
              </name>
            </person-group>
            <article-title>Clinical Outcomes of Failing to Dose-Reduce Cephalosporin Antibiotics in Older Adults with CKD.</article-title>
            <source>Clin J Am Soc Nephrol</source>
            <year>2019</year>
            <month>Feb</month>
            <day>07</day>
            <volume>14</volume>
            <issue>2</issue>
            <fpage>197</fpage>
            <page-range>197-205</page-range>
            <pub-id pub-id-type="pmid">30630861</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159953.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dallmann</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ince</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Solodenko</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Meyer</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Willmann</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Eissing</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Hempel</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Physiologically Based Pharmacokinetic Modeling of Renally Cleared Drugs in Pregnant Women.</article-title>
            <source>Clin Pharmacokinet</source>
            <year>2017</year>
            <month>Dec</month>
            <volume>56</volume>
            <issue>12</issue>
            <fpage>1525</fpage>
            <page-range>1525-1541</page-range>
            <pub-id pub-id-type="pmid">28391404</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159953.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <collab>Committee on Practice Bulletins-Obstetrics</collab>
            <article-title>ACOG Practice Bulletin No. 199: Use of Prophylactic Antibiotics in Labor and Delivery.</article-title>
            <source>Obstet Gynecol</source>
            <year>2018</year>
            <month>Sep</month>
            <volume>132</volume>
            <issue>3</issue>
            <fpage>e103</fpage>
            <page-range>e103-e119</page-range>
            <pub-id pub-id-type="pmid">30134425</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159953.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Th&#x000f8;nnings</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Jensen</surname>
                <given-names>KS</given-names>
              </name>
              <name>
                <surname>Nielsen</surname>
                <given-names>NB</given-names>
              </name>
              <name>
                <surname>Skj&#x000f8;nnemand</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hansen</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Lange</surname>
                <given-names>KHW</given-names>
              </name>
              <name>
                <surname>Frimodt-M&#x000f8;ller</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Cefuroxime pharmacokinetics and pharmacodynamics for intravenous dosage regimens with 750 mg or 1500 mg doses in healthy young volunteers.</article-title>
            <source>J Med Microbiol</source>
            <year>2020</year>
            <month>Mar</month>
            <volume>69</volume>
            <issue>3</issue>
            <fpage>387</fpage>
            <page-range>387-395</page-range>
            <pub-id pub-id-type="pmid">31958049</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159953.r40">
          <label>40</label>
          <element-citation publication-type="book">
            <chapter-title>Cephalosporins</chapter-title>
            <source>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]</source>
            <publisher-name>National Institute of Diabetes and Digestive and Kidney Diseases</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2021</year>
            <month>12</month>
            <day>20</day>
            <pub-id pub-id-type="pmid">31643977</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159953.r41">
          <label>41</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Baillargeon</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Holmes</surname>
                <given-names>HM</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>YL</given-names>
              </name>
              <name>
                <surname>Raji</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Sharma</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Kuo</surname>
                <given-names>YF</given-names>
              </name>
            </person-group>
            <article-title>Concurrent use of warfarin and antibiotics and the risk of bleeding in older adults.</article-title>
            <source>Am J Med</source>
            <year>2012</year>
            <month>Feb</month>
            <volume>125</volume>
            <issue>2</issue>
            <fpage>183</fpage>
            <page-range>183-9</page-range>
            <pub-id pub-id-type="pmid">22269622</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159953.r42">
          <label>42</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sharifzadeh</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Mohammadpour</surname>
                <given-names>AH</given-names>
              </name>
              <name>
                <surname>Tavanaee</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Elyasi</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Antibacterial antibiotic-induced drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome: a literature review.</article-title>
            <source>Eur J Clin Pharmacol</source>
            <year>2021</year>
            <month>Mar</month>
            <volume>77</volume>
            <issue>3</issue>
            <fpage>275</fpage>
            <page-range>275-289</page-range>
            <pub-id pub-id-type="pmid">33025080</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159953.r43">
          <label>43</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bailey</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Torkington</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Anthony</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Wells</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Blyth</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Jones</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Antibiotic-related acute kidney injury in patients undergoing elective joint replacement.</article-title>
            <source>Bone Joint J</source>
            <year>2014</year>
            <month>Mar</month>
            <volume>96-B</volume>
            <issue>3</issue>
            <fpage>395</fpage>
            <page-range>395-8</page-range>
            <pub-id pub-id-type="pmid">24589798</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159953.r44">
          <label>44</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Teng</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Frei</surname>
                <given-names>CR</given-names>
              </name>
            </person-group>
            <article-title>Delirium Associations with Antibiotics: A Pharmacovigilance Study of the FDA Adverse Event Reporting System (FAERS).</article-title>
            <source>Drugs Real World Outcomes</source>
            <year>2022</year>
            <month>Mar</month>
            <volume>9</volume>
            <issue>1</issue>
            <fpage>23</fpage>
            <page-range>23-29</page-range>
            <pub-id pub-id-type="pmid">34275113</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159953.r45">
          <label>45</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sultana</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Mubeen</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Arayne</surname>
                <given-names>MS</given-names>
              </name>
              <name>
                <surname>Ifzal</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Cefuroxime antacid interactions.</article-title>
            <source>Pak J Pharm Sci</source>
            <year>2001</year>
            <month>Jan</month>
            <volume>14</volume>
            <issue>1</issue>
            <fpage>1</fpage>
            <page-range>1-8</page-range>
            <pub-id pub-id-type="pmid">16414845</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159953.r46">
          <label>46</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tucker</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hegarty</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Magill</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Blaney</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Armstrong</surname>
                <given-names>LV</given-names>
              </name>
              <name>
                <surname>McCaffrey</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Beverland</surname>
                <given-names>DE</given-names>
              </name>
            </person-group>
            <article-title>Acute Kidney Injury After Prophylactic Cefuroxime and Gentamicin in Patients Undergoing Primary Hip and Knee Arthroplasty-A Propensity Score-Matched Study.</article-title>
            <source>J Arthroplasty</source>
            <year>2018</year>
            <month>Sep</month>
            <volume>33</volume>
            <issue>9</issue>
            <fpage>3009</fpage>
            <page-range>3009-3015</page-range>
            <pub-id pub-id-type="pmid">29807788</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159953.r47">
          <label>47</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gu</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Zhi</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>Cefuroxime-induced anaphylaxis with prominent central nervous system manifestations: A case report.</article-title>
            <source>J Int Med Res</source>
            <year>2019</year>
            <month>Feb</month>
            <volume>47</volume>
            <issue>2</issue>
            <fpage>1010</fpage>
            <page-range>1010-1014</page-range>
            <pub-id pub-id-type="pmid">30522387</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159953.r48">
          <label>48</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Al-Obaydi</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>CD</given-names>
              </name>
              <name>
                <surname>Foguet</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Changing prophylactic antibiotic protocol for reducing Clostridium difficile-associated diarrhoeal infections.</article-title>
            <source>J Orthop Surg (Hong Kong)</source>
            <year>2010</year>
            <month>Dec</month>
            <volume>18</volume>
            <issue>3</issue>
            <fpage>320</fpage>
            <page-range>320-3</page-range>
            <pub-id pub-id-type="pmid">21187543</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159953.r49">
          <label>49</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>McDonald</surname>
                <given-names>LC</given-names>
              </name>
              <name>
                <surname>Gerding</surname>
                <given-names>DN</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bakken</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Carroll</surname>
                <given-names>KC</given-names>
              </name>
              <name>
                <surname>Coffin</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Dubberke</surname>
                <given-names>ER</given-names>
              </name>
              <name>
                <surname>Garey</surname>
                <given-names>KW</given-names>
              </name>
              <name>
                <surname>Gould</surname>
                <given-names>CV</given-names>
              </name>
              <name>
                <surname>Kelly</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Loo</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Shaklee Sammons</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Sandora</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Wilcox</surname>
                <given-names>MH</given-names>
              </name>
            </person-group>
            <article-title>Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA).</article-title>
            <source>Clin Infect Dis</source>
            <year>2018</year>
            <month>Mar</month>
            <day>19</day>
            <volume>66</volume>
            <issue>7</issue>
            <fpage>e1</fpage>
            <page-range>e1-e48</page-range>
            <pub-id pub-id-type="pmid">29462280</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159953.r50">
          <label>50</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Al-Tawfiq</surname>
                <given-names>JA</given-names>
              </name>
            </person-group>
            <article-title>The pattern and impact of infectious diseases consultation on antimicrobial prescription.</article-title>
            <source>J Glob Infect Dis</source>
            <year>2013</year>
            <month>Apr</month>
            <volume>5</volume>
            <issue>2</issue>
            <fpage>45</fpage>
            <page-range>45-8</page-range>
            <pub-id pub-id-type="pmid">23853430</pub-id>
          </element-citation>
        </ref>
        <ref id="article-159953.r51">
          <label>51</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Deshpande</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Richter</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Haessler</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lindenauer</surname>
                <given-names>PK</given-names>
              </name>
              <name>
                <surname>Yu</surname>
                <given-names>PC</given-names>
              </name>
              <name>
                <surname>Zilberberg</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Imrey</surname>
                <given-names>PB</given-names>
              </name>
              <name>
                <surname>Higgins</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Rothberg</surname>
                <given-names>MB</given-names>
              </name>
            </person-group>
            <article-title>De-escalation of Empiric Antibiotics Following Negative Cultures in Hospitalized Patients With Pneumonia: Rates and Outcomes.</article-title>
            <source>Clin Infect Dis</source>
            <year>2021</year>
            <month>Apr</month>
            <day>26</day>
            <volume>72</volume>
            <issue>8</issue>
            <fpage>1314</fpage>
            <page-range>1314-1322</page-range>
            <pub-id pub-id-type="pmid">32129438</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
